{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:18:14Z","timestamp":1778210294158,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82171062"],"award-info":[{"award-number":["No. 82171062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04751-7","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:35:52Z","timestamp":1773822952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fellow-eye effect of intravitreal aflibercept 8mg in a patient with bilateral refractory nAMD: a case report and literature review"],"prefix":"10.1186","volume":"26","author":[{"given":"Jingfa","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"4751_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392:1147\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(18)31550-2.","journal-title":"Lancet"},{"key":"4751_CR2","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.2147\/OPTH.S533237","volume":"19","author":"T Lin","year":"2025","unstructured":"Lin T, Luo S, Zhuang C, Xiao H, Ding X, Li S. Caregiver burden among patients receiving anti-VEGF intravitreal injections for AMD and DR: a cross-sectional study in Guangzhou. Clin Ophthalmol. 2025;19:3071\u20138. https:\/\/doi.org\/10.2147\/OPTH.S533237.","journal-title":"Clin Ophthalmol"},{"key":"4751_CR3","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, et al. Intravitreal aflibercept 8\u00a0mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403:1153\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(23)02577-1.","journal-title":"Lancet"},{"key":"4751_CR4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik J-F, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8\u00a0mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1.","journal-title":"Lancet"},{"key":"4751_CR5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12886-024-03795-x","volume":"24","author":"MI Karamat","year":"2024","unstructured":"Karamat MI, Saleem H, Khakwani M, Ahmed A. Bilateral improvement in age-related macular degeneration following unilateral Aflibercept injection. BMC Ophthalmol. 2024;24:523. https:\/\/doi.org\/10.1186\/s12886-024-03795-x.","journal-title":"BMC Ophthalmol"},{"key":"4751_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8561895","volume":"2018","author":"H Isildak","year":"2018","unstructured":"Isildak H, Schwartz SG, Flynn HW. Therapeutic effect of anti-VEGF for age-related macular degeneration in the untreated fellow eye. Case Rep Ophthalmol Med. 2018;2018:1\u20134. https:\/\/doi.org\/10.1155\/2018\/8561895.","journal-title":"Case Rep Ophthalmol Med"},{"key":"4751_CR7","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1167\/iovs.17-22431","volume":"58","author":"JB Christoforidis","year":"2017","unstructured":"Christoforidis JB, Briley K, Binzel K, Bhatia P, Wei L, Kumar K, et al. Systemic biodistribution and intravitreal pharmacokinetic properties of bevacizumab, ranibizumab, and aflibercept in a nonhuman primate model. Investig Opthalmology Vis Sci. 2017;58:5636. https:\/\/doi.org\/10.1167\/iovs.17-22431.","journal-title":"Investig Opthalmology Vis Sci"},{"key":"4751_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ophtha.2023.02.021","volume":"130","author":"RN Khurana","year":"2023","unstructured":"Khurana RN, Li C, Lum F. Loss to follow-up in patients with neovascular age-related macular degeneration treated with anti\u2013VEGF therapy in the United States in the IRIS\u00ae Registry. Ophthalmology. 2023;130:672\u201383. https:\/\/doi.org\/10.1016\/j.ophtha.2023.02.021.","journal-title":"Ophthalmology"},{"key":"4751_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti\u2013vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients. Ophthalmol Retina. 2020;4:19\u201330. https:\/\/doi.org\/10.1016\/j.oret.2019.05.017.","journal-title":"Ophthalmol Retina"},{"key":"4751_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3928\/23258160-20170130-11","volume":"48","author":"E Rahimy","year":"2017","unstructured":"Rahimy E, Nyongand\u2019o O, Leng T. Significant bilateral response in diabetic macular edema after single unilateral intravitreal aflibercept injection. Ophthalmic Surg Lasers Imaging Retina. 2017;48:167\u20139. https:\/\/doi.org\/10.3928\/23258160-20170130-11.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"4751_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/eye.2014.94","volume":"28","author":"J Hanhart","year":"2014","unstructured":"Hanhart J, Tiosano L, Averbukh E, Banin E, Hemo I, Chowers I. Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema. Eye. 2014;28:646\u201353. https:\/\/doi.org\/10.1038\/eye.2014.94.","journal-title":"Eye"},{"key":"4751_CR12","doi-asserted-by":"publisher","unstructured":"Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, et al. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol (Copenh). 2015;93. https:\/\/doi.org\/10.1111\/aos.12604.","DOI":"10.1111\/aos.12604"},{"key":"4751_CR13","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98:1636\u201341. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305252.","journal-title":"Br J Ophthalmol"},{"key":"4751_CR14","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37:1847\u201358. https:\/\/doi.org\/10.1097\/IAE.0000000000001493.","journal-title":"Retina"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04751-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04751-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04751-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T01:21:13Z","timestamp":1777252873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04751-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4751"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04751-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this case report as per institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}